CERo Therapeutics Holdings (CERO) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.
The company said it expects to start the phase 1 trial in Q1 of 2025.
CERo's shares soared past 79% in recent trading.
Price: 0.34, Change: +0.15, Percent Change: +79.22
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。